|
Sara Radcliffe is the Vice President for Science and Regulatory Affairs at the Biotechnology Industry Organization (BIO). Ms. Radcliffe has responsibility for developing and implementing strategic BIO responses to scientific and regulatory issues that affect the ability of BIO's human healthcare focused companies to research and develop products, and to bring these products to market. Before joining BIO, Ms. Radcliffe was Senior Director, Biologics & Biotechnology, and Assistant Vice-President, Preclinical Drug Safety Evaluation, at the Pharmaceutical Research and Manufacturers of America (PhRMA). Among her many responsibilities at PhRMA were to staff the PhRMA Vaccines CEOs Committee and the PhRMA Emergency Preparedness Task Force (comprising CEOs of a dozen large companies). She also worked for the Alliance and Technology Group at SmithKline Beecham Pharmaceuticals as a Research and Development Policy Analyst, where her work focused on evaluation and communication of the promise, ethics, and impact of rapidly-developing technologies in DNA Research, including Pharmacogenetics. She has worked for the Core Services Committee of the New Zealand Ministry of Health, and in community health in Canada. She holds a Master's of Public Health and a Master’s in Philosophy from the Johns Hopkins University.
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.
|
Printer Friendly